Study IDs Risks to Offspring Associated With Prenatal Opioid Exposure

2024-01-20
临床结果
FRIDAY, Jan. 19, 2024 -- Prenatal opioid exposure (POE) is associated with an increased risk for infection, eczema and dermatitis, and asthma in offspring, but it is not linked to allergies or anaphylaxis, according to a study published online Jan. 17 in JAMA Network Open.
Erin Kelty, Ph.D., from the University of Western Australia in Crawley, and colleagues compared the risk for hospitalization and emergency department presentation for immune-related conditions in children with and without POE using linked administrative health records for all 401,462 children born between Jan. 1, 2003, and Dec. 31, 2018 (1,656 with POE).
The researchers found that compared with nonexposed neonates, those with POE were more likely to be born preterm, have low birth weight for gestational age, and be coexposed to cigarette smoke. The risks for perinatal infection (adjusted odds ratio [aOR], 1.62) as well as eczema and dermatitis (aOR, 11.91) were increased in association with POE versus nonexposure. Both conditions were also increased in association with neonatal abstinence syndrome (aORs, 2.91 and 31.11, respectively). An increased risk for childhood asthma was also seen in association with POE (adjusted hazard ratio, 1.44) but allergies and anaphylaxis were not. For children with POE from opioids used to treat opioid use disorder but not pain, the risk for childhood eczema and dermatitis was increased. In contrast, POE from opioids used for pain but not to treat opioid use disorder was associated with increased infection risk.
"The findings suggest that POE may modify the developing immune system, changing how the immune system responds to subsequent conditions," the authors write.
Two authors disclosed ties to Mundipharma; one author has a related patent pending.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。